Afoxolaner 68 Mg Chewable Tablets

Verify with FDA CVM →

1,663 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,663
Total Reports
39
Deaths Reported
230.0%
Death Rate

Active Ingredients

Afoxolaner 68 Mg Chewable Tablets

Administration Routes

OralUnknownOther

Species Affected

Dog 1,548
Unknown 113
Human 2

Most Affected Breeds

Crossbred Canine/dog 322
Unknown 127
Dog (unknown) 126
Collie - Border 86
Mixed (Dog) 79
Retriever - Labrador 77
Spaniel - Cocker American 52
Retriever - Golden 42
Shepherd Dog - German 41
Terrier - Bull - Staffordshire 38

Most Reported Reactions

Vomiting 341
Skin disorders NOS 313
Lack of efficacy (tick) 288
Lack of efficacy (flea) 215
Diarrhoea 174
Lethargy (see also Central nervous system depression in 'Neurological') 143
Pruritus 100
Emesis 68
Scratching 66
Anorexia 51
Lack of efficacy (ectoparasite) - NOS 48
Inappetence 46

Outcome Breakdown

Outcome Unknown
889 (57.2%)
Recovered/Normal
536 (34.5%)
Ongoing
86 (5.5%)
Died
22 (1.4%)
Euthanized
18 (1.2%)
Recovered with Sequela
3 (0.2%)

Data Summary

Metric Value
Total adverse event reports 1,663
Reports involving death 39
Case-fatality rate (reported events) 230.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Afoxolaner 68 Mg Chewable Tablets Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,663 adverse event reports referencing Afoxolaner 68 Mg Chewable Tablets, including 39 reports in which the animal died — a 230.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Afoxolaner 68 Mg Chewable Tablets. Reported administration routes include Oral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Afoxolaner 68 Mg Chewable Tablets reports are Dog (1,548 reports), Unknown (113 reports), Human (2 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (322), Unknown (127), Dog (unknown) (126) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Afoxolaner 68 Mg Chewable Tablets are Vomiting (341), Skin disorders NOS (313), Lack of efficacy (tick) (288), Lack of efficacy (flea) (215). Of the 1,554 reports with a coded outcome, Outcome Unknown is the leading category at 57.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Afoxolaner 68 Mg Chewable Tablets.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial